Drugs / EZN-2968
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01120288 | Apr 2010 → Sep 2013 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00466583 | Mar 2007 → Jun 2011 | carcinoma, lymphoma | Enzon Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EZN 2968 | “IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified.” NCT00466583 ↗ |
| Action | Inhibit | “EZN-2968 is a new type of cancer drug that goes into the cancer cell and switches off the production of the HIF protein” NCT01120288 ↗ |
| Modality | Antisense oligonucleotide | “a locked nucleic acid antisense oligonucleotide against hypoxia-inducible factor 1α” NCT00466583 ↗ |
| Route | Intravenous | “administered as a 2-hour intravenous (i.v.) infusion” NCT00466583 ↗ |
| Target | HIF1A | “EZN-2968 is an antisense oligonucleotide that specifically targets HIF-1 alpha” NCT01120288 ↗ |